The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 13, 2020

Filed:

May. 21, 2018
Applicant:

Redwood Pharma Ab, Stockholm, SE;

Inventors:

Clive H. Reading, Kent, GB;

Thomas Rowe, Roswell, GA (US);

Mario G. Fsadni, Hertfordshire, GB;

Richard Coulon, Cummings, GA (US);

Assignee:

REDWOOD PHARMA AB, Stockholm, SE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 31/568 (2006.01); A61K 31/5685 (2006.01); A61K 45/06 (2006.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 47/40 (2006.01); A61K 31/565 (2006.01); A61K 31/566 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0048 (2013.01); A61K 31/565 (2013.01); A61K 31/566 (2013.01); A61K 31/568 (2013.01); A61K 31/5685 (2013.01); A61K 45/06 (2013.01); A61K 47/32 (2013.01); A61K 47/36 (2013.01); A61K 47/40 (2013.01);
Abstract

A topical application formulation of estrogen and estrogen analogs or other estrogen receptor modulators is disclosed for the treatment of primary or secondary dry eye syndrome (also known as keratoconjunctivitis sicca (KCS)). Preferred formulations include 17-β-estradiol and its derivatives in lipid, liposomes, polymers, or aqueous or non-aqueous vehicles for the topical treatment of the ocular surface tissues particularly as time-release or micro-dose formulations. These formulations may also be useful in treating other conditions where KCS may occur, such as post-operative refractive surgery and corneal transplant patients.


Find Patent Forward Citations

Loading…